

Efficacy of once-daily, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study in Asian population

*Hironori Sagara¹, Nathalie Barbier², Tsuyoshi Ishii³, Hajime Yoshisue³,
Ivan Nikolaev², Motoi Hosoe², Yasuhiro Gon⁴

¹Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan

²Novartis Pharma AG, Basel, Switzerland

³Novartis Pharma K.K., Tokyo, Japan

⁴Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

***Corresponding author**

Prof. Hironori Sagara

1-5-8 Hatanodai, Shinagawa-ku,

Tokyo, Japan

Zip code: 142-8666

Phone: +81-3-3784-8704

Email: sagarah@med.showa-u.ac.jp

Figure S1: Change from baseline in post-dose FEV₁ (5 min–1 h) with IND/GLY/MF, IND/MF and SAL/FLU at different time points on Day 1 (full analysis set)

IND/GLY/MF medium-dose, IND/GLY/MF 150/50/80 µg o.d.; IND/GLY/MF high-dose, IND/GLY/MF 150/50/160 µg o.d.; IND/MF medium-dose, IND/MF 150/160 µg o.d.; IND/MF high-dose, IND/MF 150/320 µg o.d.; SAL/FLU high-dose, SAL/FLU 50/500 µg b.i.d.

Data presented as LS mean

Δ, treatment difference; b.i.d., twice-daily; FEV₁, forced expiratory volume in 1 second;

IND/MF, indacaterol acetate/mometasone furoate; IND/GLY/MF, indacaterol

acetate/glycopyrronium bromide/mometasone furoate; LS, least square; o.d., once-daily;

SAL/FLU, salmeterol xinafoate/fluticasone propionate

Figure S2: Change from baseline in ACQ-7 score with IND/GLY/MF versus IND/MF and SAL/FLU at Week 52 (full analysis set)

IND/GLY/MF medium-dose, IND/GLY/MF 150/50/80 µg o.d.; IND/GLY/MF high-dose, IND/GLY/MF 150/50/160 µg o.d.; IND/MF medium-dose, IND/MF 150/160 µg o.d.; IND/MF high-dose, IND/MF 150/320 µg o.d.; SAL/FLU high-dose, SAL/FLU 50/500 µg b.i.d.

Data presented as LS mean ± SE, error bars represent SE values.

Δ, treatment difference; ACQ, Asthma Control Questionnaire; b.i.d., twice-daily;

IND/MF, indacaterol acetate/mometasone furoate; IND/GLY/MF, indacaterol

acetate/glycopyrronium bromide/mometasone furoate; LS, least square; o.d.,

once-daily; SAL/FLU, salmeterol xinafoate/fluticasone propionate